Clinical and electrophysiologic profile of Brugada syndrome in Iranian patients.
Clinical and electrophysiologic characteristics of 20 patients (15 males; mean age, 42 +/- 9 years) with Brugada syndrome were studied. Electrocardiographic abnormalities (spontaneous in 6 and provoked in 14) were recognized in 5 symptomatic and 15 asymptomatic patients. Mean PR (188 +/- 18 vs. 184 +/- 24 ms) and QT (362 +/- 34 vs. 382 +/- 28 ms) intervals and ST-segment elevation (2.28 +/- 0.42 vs. 2.70 +/- 0.77 mm) were similar in both groups. The PR interval was slightly longer in males than females (191 +/- 21 vs.168 +/- 18 ms, p = 0.042), but ST-segment elevation (2.70 +/- 0.78 vs. 2.24 +/- 0.26 mm) was similar. The HV interval was longer in males than females (57 +/- 4 vs. 50 +/- 4 ms, p = 0.047). Ventricular arrhythmias were induced in 40% of asymptomatic patients. There was no significant difference in age, sex, PR interval, ST-segment elevation, or HV interval between inducible and non-inducible patients. A defibrillator was implanted in 8 patients. During 16 +/- 2 months of follow-up, one symptomatic patient had appropriate device therapy. None of the asymptomatic and non-inducible patients experienced a cardiac event. Electrophysiologic data have no role in predicting inducibility in programmed stimulation.
Haghjoo
Majid
M
Department of Pacemaker and Electrophysiology, Shahid Rajaie Cardiovascular Center, Mellat Park, Vali-E-Asr Avenue, Tehran 1996911151, Iran. haghjoo@rhc.ac.ir
Arya
Arash
A
Emkanjoo
Zahra
Z
Sadr-Ameli
Mohammad Ali
MA
D000328:Adult; D000889:Anti-Arrhythmia Agents; D002037:Bundle-Branch Block / Q000503:physiopathology* / Q000628:therapy; D017147:Defibrillators, Implantable; D004558:Electric Stimulation; D004562:Electrocardiography; D022062:Electrophysiologic Techniques, Cardiac; D005260:Female; D005424:Flecainide; D006801:Humans; D007492:Iran; D008297:Male; D008875:Middle Aged; D012737:Sex Factors; D013575:Syncope / Q000209:etiology / Q000503:physiopathology; D013577:Syndrome; D017180:Tachycardia, Ventricular / Q000503:physiopathology* / Q000628:therapy; D014693:Ventricular Fibrillation / Q000503:physiopathology* / Q000628:therapy
D000889:Anti-Arrhythmia Agents; D005424:Flecainide